Rep. Robert Bresnahan, Jr. Sells Off Shares of Danaher Co. (NYSE:DHR)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Danaher Co. (NYSE:DHR). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $15,001 and $50,000 in Danaher stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Danaher Stock Down 2.1 %

Shares of NYSE:DHR opened at $205.69 on Friday. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock’s 50-day moving average price is $214.57 and its 200-day moving average price is $236.90. The stock has a market capitalization of $147.01 billion, a P/E ratio of 38.96, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the company posted $2.09 EPS. On average, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.62%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio is presently 24.24%.

Institutional Investors Weigh In On Danaher

Large investors have recently added to or reduced their stakes in the stock. Heck Capital Advisors LLC purchased a new stake in Danaher during the fourth quarter valued at $27,000. Decker Retirement Planning Inc. bought a new stake in shares of Danaher during the 4th quarter valued at about $31,000. Golden State Wealth Management LLC purchased a new stake in shares of Danaher during the 4th quarter valued at about $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the 3rd quarter worth approximately $39,000. Finally, Hurley Capital LLC bought a new stake in Danaher during the fourth quarter valued at approximately $34,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 11.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on DHR shares. Scotiabank started coverage on shares of Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target for the company. Raymond James reissued a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $277.00 price target (down previously from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Guggenheim assumed coverage on Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective on the stock. Finally, Jefferies Financial Group decreased their target price on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $278.24.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.